 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Current Price	$1.61
Prev Close	$1.63
Open	$1.62
Dividend Yield	0.00%
50-Day Moving Average	$1.81
Beta	1.51
Avg. Volume	56,951.58
PE Ratio	0.44

52-Week High	$7.20
52-Week Low	$1.53
Market Capitalization	$12.03M
EPS	$3.75
Price to Book	0.51
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.17

APVO Aptevo Therapeutics Inc

About

Feed

Fundamentals

News